Literature DB >> 18976921

KIR-HLA intercourse in HIV disease.

Mary Carrington1, Maureen P Martin, Jeroen van Bergen.   

Abstract

Human leukocyte antigen (HLA) class I loci are essential to an effective immune response against a wide variety of pathogenic microorganisms, and they represent the prototypes for genetic polymorphism that are sustained through balancing selection. The functional significance of HLA class I variation is better exemplified by studies involving HIV type 1 (HIV-1) than any other infectious organism. HLA class I molecules are essential to the acquired immune response, but they are also important in innate immunity as ligands for the killer cell immunoglobulin-like receptors (KIR), which modulate natural killer cell activity. Here we concentrate on the interaction between the HLA-B and KIR3DL1/KIR3DS1 genes, describe the effects of these loci on HIV disease, and discuss questions that remain unresolved.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18976921      PMCID： PMC3463869          DOI： 10.1016/j.tim.2008.09.002

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN： 0966-842X            Impact factor:   17.079


  81 in total

1.  Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk.

Authors:  P A Zimmerman; A Buckler-White; G Alkhatib; T Spalding; J Kubofcik; C Combadiere; D Weissman; O Cohen; A Rubbert; G Lam; M Vaccarezza; P E Kennedy; V Kumaraswami; J V Giorgi; R Detels; J Hunter; M Chopek; E A Berger; A S Fauci; T B Nutman; P M Murphy
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

2.  Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor.

Authors:  J E Gumperz; L D Barber; N M Valiante; L Percival; J H Phillips; L L Lanier; P Parham
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

Review 3.  Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors.

Authors:  D H Raulet; W Held; I Correa; J R Dorfman; M F Wu; L Corral
Journal:  Immunol Rev       Date:  1997-02       Impact factor: 12.988

4.  Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS.

Authors:  P J Goulder; R E Phillips; R A Colbert; S McAdam; G Ogg; M A Nowak; P Giangrande; G Luzzi; B Morgan; A Edwards; A J McMichael; S Rowland-Jones
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

5.  Threonine 80 on HLA-B27 confers protection against lysis by a group of natural killer clones.

Authors:  I Luque; R Solana; M D Galiani; R González; F García; J A López de Castro; J Peña
Journal:  Eur J Immunol       Date:  1996-08       Impact factor: 5.532

Review 6.  Cytomegaloviruses use multiple mechanisms to elude the host immune response.

Authors:  E Wiertz; A Hill; D Tortorella; H Ploegh
Journal:  Immunol Lett       Date:  1997-06-01       Impact factor: 3.685

Review 7.  Host MHC class I gene control of NK-cell specificity in the mouse.

Authors:  P Höglund; J Sundbäck; M Y Olsson-Alheim; M Johansson; M Salcedo; C Ohlén; H G Ljunggren; C L Sentman; K Kärre
Journal:  Immunol Rev       Date:  1997-02       Impact factor: 12.988

8.  Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors.

Authors:  N M Valiante; M Uhrberg; H G Shilling; K Lienert-Weidenbach; K L Arnett; A D'Andrea; J H Phillips; L L Lanier; P Parham
Journal:  Immunity       Date:  1997-12       Impact factor: 31.745

9.  Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.

Authors:  M Samson; F Libert; B J Doranz; J Rucker; C Liesnard; C M Farber; S Saragosti; C Lapoumeroulie; J Cognaux; C Forceille; G Muyldermans; C Verhofstede; G Burtonboy; M Georges; T Imai; S Rana; Y Yi; R J Smyth; R G Collman; R W Doms; G Vassart; M Parmentier
Journal:  Nature       Date:  1996-08-22       Impact factor: 49.962

10.  Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Authors:  M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728
View more
  63 in total

1.  A comprehensive analysis of the binding of anti-KIR antibodies to activating KIRs.

Authors:  K Czaja; A-S Borer; L Schmied; G Terszowski; M Stern; A Gonzalez
Journal:  Genes Immun       Date:  2013-10-31       Impact factor: 2.676

2.  Association of KIR3DL1/S1 and HLA-Bw4 with CD4 T cell counts in HIV-infected Mexican mestizos.

Authors:  Daniel Hernández-Ramírez; Mario A Esparza-Pérez; José L Ramirez-Garcialuna; J Rafael Arguello; Peter B Mandeville; Daniel E Noyola; Christian A García-Sepúlveda
Journal:  Immunogenetics       Date:  2015-06-03       Impact factor: 2.846

Review 3.  HIV and HLA class I: an evolving relationship.

Authors:  Philip J R Goulder; Bruce D Walker
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

4.  Regulatory variation in HIV-1 dependency factor ZNRD1 associates with host resistance to HIV-1 acquisition.

Authors:  Ping An; James J Goedert; Sharyne Donfield; Susan Buchbinder; Gregory D Kirk; Roger Detels; Cheryl A Winkler
Journal:  J Infect Dis       Date:  2014-05-19       Impact factor: 5.226

5.  Multiple KIR gene polymorphisms are associated with plasma viral loads in SIV-infected rhesus macaques.

Authors:  Porntip Chaichompoo; Pavel Bostik; Susan Stephenson; Suthiphol Udompunturuk; Jaruda Kobkitjaroen; Kovit Pattanapanyasat; Aftab A Ansari
Journal:  Cell Immunol       Date:  2010-04-01       Impact factor: 4.868

6.  The D0 Ig-like domain plays a central role in the stronger binding of KIR3DL2 to B27 free H chain dimers.

Authors:  Hiroko Hatano; Jacqueline Shaw; Kaitlin Marquardt; Zhiyong Zhang; Laurent Gauthier; Stephanie Chanteux; Benjamin Rossi; Demin Li; Julie Mitchell; Simon Kollnberger
Journal:  J Immunol       Date:  2015-01-12       Impact factor: 5.422

7.  Dynamics of viremia in primary HIV-1 infection in Africans: insights from analyses of host and viral correlates.

Authors:  Heather A Prentice; Matthew A Price; Travis R Porter; Emmanuel Cormier; Michael J Mugavero; Anatoli Kamali; Etienne Karita; Shabir Lakhi; Eduard J Sanders; Omu Anzala; Pauli N Amornkul; Susan Allen; Eric Hunter; Richard A Kaslow; Jill Gilmour; Jianming Tang
Journal:  Virology       Date:  2013-12-12       Impact factor: 3.616

8.  HIV Type 1 Disease Progression to AIDS and Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable Subtype and T-Cell Immune Activation Levels.

Authors:  Michael A Eller; Marc S Opollo; Michelle Liu; Andrew D Redd; Leigh Anne Eller; Cissy Kityo; Joshua Kayiwa; Oliver Laeyendecker; Maria J Wawer; Mark Milazzo; Noah Kiwanuka; Ronald H Gray; David Serwadda; Nelson K Sewankambo; Thomas C Quinn; Nelson L Michael; Fred Wabwire-Mangen; Johan K Sandberg; Merlin L Robb
Journal:  J Infect Dis       Date:  2014-11-17       Impact factor: 5.226

9.  Epstein-Barr virus negativity among individuals older than 60 years is associated with HLA-C and HLA-Bw4 variants and tonsillectomy.

Authors:  Bojana Durovic; Olivier Gasser; Patrick Gubser; Jörg Sigle; Hans H Hirsch; Martin Stern; Andreas Buser; Christoph Hess
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

10.  KIR2DL4 copy number variation is associated with CD4+ T-cell depletion and function of cytokine-producing NK cell subsets in SIV-infected Mamu-A*01-negative rhesus macaques.

Authors:  Ina Hellmann; Norman L Letvin; Jörn E Schmitz
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.